These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 13129490)

  • 61. [Topotecan, a recent discovery and prospects for treating tumors of the lung].
    Gridelli C
    Tumori; 1999; 85(6 Suppl 1):S16-22. PubMed ID: 10786196
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.
    Lankester KJ; Taylor NJ; Stirling JJ; Boxall J; D'Arcy JA; Leach MO; Rustin GJ; Padhani AR
    Br J Cancer; 2005 Oct; 93(9):979-85. PubMed ID: 16234826
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment advances in ovarian cancer.
    Almadrones LA
    Cancer Nurs; 2003 Dec; 26(6 Suppl):16S-20S. PubMed ID: 15025408
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Update on first-line treatment of advanced ovarian carcinoma.
    Kemp Z; Ledermann J
    Int J Womens Health; 2013; 5():45-51. PubMed ID: 23378788
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Current status of maintenance therapy for advanced ovarian cancer.
    Hope JM; Blank SV
    Int J Womens Health; 2010 Aug; 1():173-80. PubMed ID: 21072286
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers.
    Mercier AM; Shahzad MM
    Ann Transl Med; 2023 Mar; 11(6):275. PubMed ID: 37082657
    [No Abstract]   [Full Text] [Related]  

  • 67. Nucleic acid vaccination strategies for ovarian cancer.
    Saha C; Bojdo J; Dunne NJ; Duary RK; Buckley N; McCarthy HO
    Front Bioeng Biotechnol; 2022; 10():953887. PubMed ID: 36420446
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment.
    Hu Y; Ran M; Wang B; Lin Y; Cheng Y; Zheng S
    Int J Nanomedicine; 2020; 15():9703-9715. PubMed ID: 33299312
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Artificial Mini Dendritic Cells Boost T Cell-Based Immunotherapy for Ovarian Cancer.
    Cheng S; Xu C; Jin Y; Li Y; Zhong C; Ma J; Yang J; Zhang N; Li Y; Wang C; Yang Z; Wang Y
    Adv Sci (Weinh); 2020 Apr; 7(7):1903301. PubMed ID: 32274314
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.
    Abdel Azim S; Duggan-Peer M; Sprung S; Reimer D; Fiegl H; Soleiman A; Marth C; Zeimet AG
    Oncotarget; 2016 Jun; 7(24):37205-37214. PubMed ID: 27174921
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.
    Chiang YC; Lin HW; Chang CF; Chang MC; Fu CF; Chen TC; Hsieh SF; Chen CA; Cheng WF
    Oncotarget; 2015 Nov; 6(37):39740-55. PubMed ID: 26452028
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas.
    Chen CA; Chiang YC; Chang MC; Hu YH; You SL; Cheng YY; Chou CY; Cheng WF
    Am J Transl Res; 2015; 7(1):139-52. PubMed ID: 25755836
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p19(INK4d) mRNA and protein expression as new prognostic factors in ovarian cancer patients.
    Felisiak-Golabek A; Dansonka-Mieszkowska A; Rzepecka IK; Szafron L; Kwiatkowska E; Konopka B; Podgorska A; Rembiszewska A; Kupryjanczyk J
    Cancer Biol Ther; 2013 Oct; 14(10):973-81. PubMed ID: 24022213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Maintenance chemotherapy for ovarian cancer.
    Mei L; Chen H; Wei DM; Fang F; Liu GJ; Xie HY; Wang X; Zou J; Han X; Feng D
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD007414. PubMed ID: 23813336
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Formulation and evaluation of oral microparticulate ovarian cancer vaccines.
    Tawde SA; Chablani L; Akalkotkar A; D'Souza C; Chiriva-Internati M; Selvaraj P; D'Souza MJ
    Vaccine; 2012 Aug; 30(38):5675-81. PubMed ID: 22750042
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.
    Felisiak-Golabek A; Rembiszewska A; Rzepecka IK; Szafron L; Madry R; Murawska M; Napiorkowski T; Sobiczewski P; Osuch B; Kupryjanczyk J;
    J Ovarian Res; 2011 Nov; 4(1):20. PubMed ID: 22075440
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities.
    Langland GT; Yannone SM; Langland RA; Nakao A; Guan Y; Long SB; Vonguyen L; Chen DJ; Gray JW; Chen F
    Oncol Rep; 2010 Apr; 23(4):1021-6. PubMed ID: 20204287
    [TBL] [Abstract][Full Text] [Related]  

  • 78. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma.
    Samanta AK; Huang HJ; Le XF; Mao W; Lu KH; Bast RC; Liao WS
    Cancer; 2009 Sep; 115(17):3897-908. PubMed ID: 19517469
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Population pharmacokinetics and dosing recommendations for cisplatin during intraperitoneal peroperative administration: development of a limited sampling strategy for toxicity risk assessment.
    Royer B; Jullien V; Guardiola E; Heyd B; Chauffert B; Kantelip JP; Pivot X
    Clin Pharmacokinet; 2009; 48(3):169-80. PubMed ID: 19385710
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma.
    Cheng WF; Huang CY; Chang MC; Hu YH; Chiang YC; Chen YL; Hsieh CY; Chen CA
    Br J Cancer; 2009 Apr; 100(7):1144-53. PubMed ID: 19293794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.